Mounjaro®
Starting from £179.99/mo
Start journey Learn moreRestless legs are not listed as a known side effect of Mounjaro (tirzepatide) in the medicine's UK prescribing information, and there is currently no clinical trial evidence linking the two directly. That said, people do report leg discomfort while on treatment, and understanding why that happens matters. Mounjaro is a prescription-only medicine; any new symptom you notice on it deserves a proper clinical conversation, not a forum guess. Below is what the evidence currently shows — and what it does not.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A belief circulates online that restless legs are a predictable side effect of Mounjaro, sometimes with confident-sounding explanations attached. It is worth setting that down gently: the medicine's official UK prescribing information does not list restless legs syndrome among the known adverse effects of tirzepatide. The large SURMOUNT-1 trial, which followed thousands of adults over 72 weeks, did not report RLS as a treatment-emergent finding. So if you have read that restless legs and Mounjaro go hand in hand, the published evidence does not back that up, at least not as a direct, established effect.
That does not mean your experience is wrong. It means the cause may be elsewhere, and finding it is more useful than assuming the medicine is to blame. Our prescribers field questions like this most weeks; a structured review of your symptoms is usually far more illuminating than a search result.
If you have noticed any leg discomfort alongside other skin changes, it is worth reading about Mounjaro rash on legs, which covers a separate and better-characterised phenomenon.
Even though RLS is not a confirmed tirzepatide side effect, that does not mean people are imagining what they feel. Several things happening during weight-loss treatment could reasonably produce leg symptoms, and they are worth knowing about.
Rapid or substantial weight loss can alter how the body manages iron. Low iron stores are one of the best-established triggers for restless legs syndrome, and people losing weight quickly sometimes experience changes in dietary intake (eating less overall, with altered meal patterns) that affect micronutrient levels. GLP-1 medicines reduce appetite considerably, and if protein, iron-rich foods, or B-vitamins slip through the gaps, leg symptoms can follow. The dos and don'ts during Mounjaro treatment page covers nutritional priorities in more detail.
Sleep architecture can also shift during weight loss, particularly if sleep apnoea improves quickly (which is a documented benefit of tirzepatide) because the nervous system adjusts to the change. Restless legs symptoms are common in people with disrupted sleep, creating a connection that is real but indirect. Dehydration from reduced fluid intake or from gastrointestinal side effects such as nausea and diarrhoea is another factor worth considering; muscle cramping and uncomfortable leg sensations can both follow from poor hydration.
For a broader look at leg-related experiences people report on this medicine, the page on achy legs and Mounjaro covers muscle ache specifically.
Most leg discomfort that emerges early in treatment settles without intervention, particularly if it is linked to dietary adjustment or transient GI side effects. Symptoms worth flagging promptly to a prescriber include: an irresistible urge to move the legs that is worse at rest and at night, symptoms that began precisely when a dose was increased, or discomfort severe enough to interrupt sleep regularly.
A prescriber will typically want to know when symptoms started relative to your dosing schedule, whether they vary across the week, and what your diet and fluid intake look like. Blood tests checking ferritin, B12 and folate are a reasonable starting point if RLS is suspected; these are straightforward for a GP to arrange. You can see more detail about general leg symptoms during treatment on the Mounjaro and legs overview.
Tirzepatide itself is assessed before every prescription at nume, every repeat order goes through a clinical re-review, not an automated renewal. If something has changed in how you feel, that review is the right moment to raise it. You can find general guidance on what to do if a dose timing shifts at the late dose page, which also touches on how timing affects tolerability.
Do not stop or alter your dose without speaking to your prescriber first; missing doses can cause its own disruptions. Instead, keep a short symptom diary noting time of day, which leg or both, how long symptoms last, and whether movement relieves them. That information makes the clinical conversation far more productive.
Check your dietary pattern honestly. People on effective GLP-1 treatment often eat significantly less than before, and it is easy for iron, magnesium, or B-vitamins to fall quietly short. A dietitian or your prescriber can advise on whether supplementation makes sense; this is not something to self-manage with high-dose supplements, which carry their own risks.
If you are already on treatment and want to understand the full picture of how tirzepatide works and what effects are and are not established, the tirzepatide overview covers the mechanism and licensed evidence base. The cost context page is there if you are weighing up whether private treatment is the right route at this stage.
For anything that feels urgent or is getting worse, contact your prescriber directly, or reach our team through the contact page. And if you have not yet started treatment and are exploring whether Mounjaro is right for you, a free consultation with one of our prescribers is a sensible first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.